Last reviewed · How we verify
Budesonide Powder
Budesonide Powder, marketed by Cardresearch, is an established product in the respiratory therapy segment with a key composition patent expiring in 2028. Its primary strength lies in its well-established market presence and the extended patent protection, which helps maintain competitive barriers. The primary risk is the potential increase in generic competition following the 2028 patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Budesonide Powder |
|---|---|
| Also known as | Fluvoxamine Maleate 100 MG [Luvox], Steroid, Placebo Pulmicort Respules®, Eohilia, Symbicort |
| Sponsor | Cardresearch |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects (PHASE1)
- Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels (PHASE4)
- Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler (NA)
- Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome (NA)
- Anti-Inflammatory Reliever South Africa (PHASE3)
- ED-Initiated School-based Asthma Medication Supervision (PHASE4)
- Asthma Research in Children and Adolescents
- Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budesonide Powder CI brief — competitive landscape report
- Budesonide Powder updates RSS · CI watch RSS
- Cardresearch portfolio CI